Skip to main content
Premium Trial:

Request an Annual Quote

T2 Biosystems Closes $34.1M Public Offering

NEW YORK (GenomeWeb) – T2 Biosystems has closed its public offering of 3.5 million shares of common stock, raising gross proceeds of $34.1 million.

T2 Bio priced the offering at $9.75 per share. In September, the firm filed to sell up to $100 million of its common stock in one or more offerings.

Goldman Sachs acted as book-running manager for the offering. Additional underwriters included Leerink Partners, Canaccord Genuity, and Cantor Fitzgerald.

T2 Bio said in a statement that it has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock at the public offering price, less the underwriting discount.

The Lexington, Massachusetts-based firm is developing molecular diagnostics for in vitro clinical applications on its T2 Magnetic Resonance detection platform.

In morning trading on the Nasdaq, shares of T2 Bio were trading down less than one percent at $9.24.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.